BAKER BROS. ADVISORS LP Q1 2018 Filing
Filed May 15, 2018
Portfolio Value
$11.8B
Holdings
114
Report Date
Q1 2018
Filing Type
13F-HR
All Holdings (114 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 34,230,751 | $2.9T | 24177.41% | |
| 2 | SGENEURSeattle Genetics, Inc. | 49,575,409 | $2.6T | 21993.39% | |
| 3 | ONCBeiGene, Ltd. | 5,829,429 | $979.3B | 8300.94% | |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | 8,555,894 | $953.6B | 8083.07% | |
| 5 | BMRNBioMarin Pharmaceutical Inc. | 7,583,084 | $614.8B | 5210.73% | |
| 6 | ACADACADIA Pharmaceuticals Inc. | 27,228,338 | $611.8B | 5185.81% | |
| 7 | —Genomic Health, Inc. | 13,789,936 | $431.5B | 3657.29% | |
| 8 | ASNDAscendis Pharma A/S | 2,837,352 | $185.6B | 1572.84% | |
| 9 | —Aquinox Pharmaceuticals, Inc. | 10,934,154 | $154.0B | 1304.91% | |
| 10 | —AveXis, Inc. | 1,167,157 | $144.2B | 1222.56% | |
| 11 | HRTXHeron Therapeutics, Inc. | 5,025,298 | $138.7B | 1175.61% | |
| 12 | —DBV Technologies S.A. | 5,509,560 | $127.1B | 1077.35% | |
| 13 | —Ablynx NV | 2,176,802 | $118.8B | 1006.66% | |
| 14 | SG7Sage Therapeutics, Inc. | 646,828 | $104.2B | 883.07% | |
| 15 | ARRYEURArray BioPharma Inc. | 5,656,196 | $92.3B | 782.41% | |
| 16 | —Spark Therapeutics, Inc. | 1,384,130 | $92.2B | 781.23% | |
| 17 | NBIXNeurocrine Biosciences, Inc. | 944,624 | $78.3B | 663.99% | |
| 18 | MRTXEURMirati Therapeutics, Inc. | 2,549,461 | $78.3B | 663.40% | |
| 19 | ARGXargenx SE | 961,754 | $77.4B | 655.73% | |
| 20 | MDGLMadrigal Pharmaceuticals, Inc. | 615,684 | $71.9B | 609.48% | |
| 21 | —Idera Pharmaceuticals, Inc. | 38,641,462 | $71.1B | 602.65% | |
| 22 | AMRNAmarin Corporation plc | 22,669,509 | $68.2B | 578.36% | |
| 23 | BCRXBioCryst Pharmaceuticals, Inc. | 14,012,172 | $66.8B | 566.52% | |
| 24 | ERYP1EURERYTECH Pharma S.A. | 3,090,069 | $64.9B | 550.02% | |
| 25 | NVAX 3.75 02/01/23Novavax, Inc. | 88,500,000 | $61.9B | 524.36% | |
| 26 | CERSCerus Corporation | 10,749,937 | $58.9B | 499.32% | |
| 27 | CBAYUSDCymaBay Therapeutics, Inc. | 3,917,700 | $50.9B | 431.35% | |
| 28 | RYTMRhythm Pharmaceuticals, Inc. | 2,049,020 | $40.8B | 345.61% | |
| 29 | NVTA1EURInvitae Corporation | 8,399,411 | $39.4B | 333.90% | |
| 30 | —bluebird bio, Inc. | 200,000 | $34.1B | 289.46% | |
| 31 | —Abeona Therapeutics Inc. | 2,184,364 | $31.3B | 265.69% | |
| 32 | HALOHalozyme Therapeutics, Inc. | 1,581,424 | $31.0B | 262.59% | |
| 33 | GBYSangamo Therapeutics, Inc. | 1,607,579 | $30.5B | 258.89% | |
| 34 | NKTREURNektar Therapeutics | 275,396 | $29.3B | 248.04% | |
| 35 | —Bellicum Pharmaceuticals, Inc. | 4,151,578 | $27.2B | 230.84% | |
| 36 | —Menlo Therapeutics Inc. | 700,000 | $26.3B | 222.97% | |
| 37 | XNCRXencor, Inc. | 872,072 | $26.1B | 221.61% | |
| 38 | GLPGGalapagos NV | 259,894 | $25.9B | 219.76% | |
| 39 | EX9Exelixis, Inc. | 1,162,644 | $25.8B | 218.28% | |
| 40 | —GW Pharmaceuticals plc | 221,800 | $25.0B | 211.82% | |
| 41 | MRUSMerus N.V. | 1,160,014 | $21.5B | 182.19% | |
| 42 | —Aimmune Therapeutics, Inc. | 673,908 | $21.4B | 181.81% | |
| 43 | —Endocyte, Inc. | 2,277,799 | $20.7B | 175.50% | |
| 44 | NTLAIntellia Therapeutics, Inc. | 833,795 | $17.6B | 149.05% | |
| 45 | —Progenics Pharmaceuticals, Inc. | 2,306,184 | $17.2B | 145.82% | |
| 46 | IM8NInsmed Incorporated | 700,000 | $15.8B | 133.62% | |
| 47 | —MyoKardia, Inc. | 290,264 | $14.2B | 120.06% | |
| 48 | BMRN 0.599 08/01/24BioMarin Pharmaceutical Inc. | 15,000,000 | $14.1B | 119.50% | |
| 49 | —BioMarin Pharmaceutical Inc. | 12,228,000 | $12.5B | 106.26% | |
| 50 | —Audentes Therapeutics, Inc. | 393,222 | $11.8B | 100.15% | |
| 51 | QUREuniQure N.V. | 500,000 | $11.8B | 99.59% | |
| 52 | AERIEURAerie Pharmaceuticals, Inc. | 215,655 | $11.7B | 99.16% | |
| 53 | —ContraFect Corporation | 7,153,076 | $11.6B | 98.53% | |
| 54 | AGLEUSDAeglea BioTherapeutics, Inc. | 1,137,872 | $11.3B | 95.68% | |
| 55 | —Corsicanto II Designated Activity Company | 10,000,000 | $11.0B | 93.45% | |
| 56 | —Achillion Pharmaceuticals, Inc. | 2,856,637 | $10.6B | 89.83% | |
| 57 | CPRXCatalyst Pharmaceuticals, Inc. | 4,381,072 | $10.5B | 88.75% | |
| 58 | VNDAVanda Pharmaceuticals Inc. | 600,354 | $10.1B | 85.74% | |
| 59 | ASMBAssembly Biosciences, Inc. | 193,787 | $9.5B | 80.72% | |
| 60 | ANABAnaptysBio, Inc. | 91,086 | $9.5B | 80.35% | |
| 61 | MGNXMacroGenics, Inc. | 363,676 | $9.2B | 77.56% | |
| 62 | GLYCEURGlycoMimetics, Inc. | 563,312 | $9.1B | 77.50% | |
| 63 | RIGLUSDRigel Pharmaceuticals, Inc. | 2,518,882 | $8.9B | 75.58% | |
| 64 | —Foamix Pharmaceuticals Ltd. | 1,598,991 | $8.2B | 69.53% | |
| 65 | —Aevi Genomic Medicine, Inc. | 4,055,142 | $8.2B | 69.09% | |
| 66 | BDQMAlbireo Pharma, Inc. | 250,000 | $8.1B | 69.02% | |
| 67 | —Syros Pharmaceuticals, Inc. | 574,835 | $7.5B | 63.24% | |
| 68 | —Aegerion Pharmaceuticals, Inc. | 9,517,000 | $7.3B | 61.65% | |
| 69 | XLRNAcceleron Pharma Inc. | 163,900 | $6.4B | 54.31% | |
| 70 | GTHXEURG1 Therapeutics, Inc. | 169,492 | $6.3B | 53.23% | |
| 71 | ALKSAlkermes plc | 100,251 | $5.8B | 49.25% | |
| 72 | IFRXInflaRx N.V. | 200,000 | $5.8B | 48.89% | |
| 73 | —Spring Bank Pharmaceuticals, Inc. | 373,144 | $5.7B | 48.64% | |
| 74 | CCXIEURChemoCentryx, Inc. | 414,029 | $5.6B | 47.73% | |
| 75 | —Momenta Pharmaceuticals, Inc. | 308,500 | $5.6B | 47.46% | |
| 76 | —Inotek Pharmaceuticals Corp. | 5,000,000 | $4.8B | 40.64% | |
| 77 | —Nabriva Therapeutics plc | 938,235 | $4.7B | 40.00% | |
| 78 | —La Jolla Pharmaceutical Company | 154,675 | $4.6B | 39.04% | |
| 79 | SLDBSolid Biosciences Inc. | 587,884 | $4.4B | 37.37% | |
| 80 | —Stemline Therapeutics, Inc. | 287,827 | $4.4B | 37.33% | |
| 81 | NVAXNovavax, Inc. | 2,000,000 | $4.2B | 35.60% | |
| 82 | —Adamas Pharmaceuticals, Inc. | 172,630 | $4.1B | 34.97% | |
| 83 | CRBPEURCorbus Pharmaceuticals Holdings, Inc. | 660,714 | $4.0B | 34.16% | |
| 84 | —Clementia Pharmaceuticals Inc. | 250,000 | $3.8B | 32.11% | |
| 85 | —NewLink Genetics Corporation | 507,273 | $3.7B | 31.17% | |
| 86 | TREURTrillium Therapeutics Inc. | 409,323 | $2.9B | 24.98% | |
| 87 | TTPHEURTetraphase Pharmaceuticals, Inc. | 935,000 | $2.9B | 24.33% | |
| 88 | —Versartis, Inc. | 1,426,310 | $2.4B | 19.94% | |
| 89 | JNCEEURJounce Therapeutics, Inc. | 100,000 | $2.2B | 18.94% | |
| 90 | NTRANatera, Inc. | 228,676 | $2.1B | 17.97% | |
| 91 | —Tonix Pharmaceuticals Holdings Corp. | 699,500 | $2.1B | 17.78% | |
| 92 | KRYSKrystal Biotech, Inc. | 200,000 | $2.0B | 17.10% | |
| 93 | OVIDOvid Therapeutics Inc. | 247,733 | $1.8B | 14.84% | |
| 94 | CLLSCellectis S.A. | 50,000 | $1.6B | 13.36% | |
| 95 | —Trevena, Inc. | 950,000 | $1.6B | 13.21% | |
| 96 | —Sunesis Pharmaceuticals, Inc. | 556,665 | $1.5B | 12.83% | |
| 97 | DVAXDynavax Technologies Corporation | 75,000 | $1.5B | 12.62% | |
| 98 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $1.2B | 10.33% | |
| 99 | —MediWound Ltd. | 226,000 | $1.2B | 9.96% | |
| 100 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $1.1B | 9.52% |
Page 1 of 2Next